Grab Sources And More Key Details Here.
And as I mentioned above, NTRB has 5 key potential catalysts to soak in now. Here they are:
No. 1 NTRB Potential Catalyst - Low Float Volatility Could Take Hold At A Moment's Notice
According to the Yahoo Finance website, NTRB has a low float.
The website reports this profile to have approximately 4.18Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news early this year help provide a near term spark?
No. 2 NTRB Potential Catalyst - Analyst From Zacks SCR Provides Massive $10 Target
Back in October of 2022, M. Marin, an analyst with Zacks Small-Cap Research, provided NTRB with a $10.00 target.
From Monday's closing valuation, that provides NTRB with over 139% potential upside.
Here's some key highlights from the report:
Given NTRB’s steps to expand its operating footprint and protect its IP, we are optimistic about AVERSA’s commercial prospects, as the potential range of applicable uses for the AVERSA technology, the rising incidences of overdose deaths and high related healthcare costs could translate, we believe, into high demand for AVERSA following clinical studies.
We are encouraged by the estimates from Health Advances. We believe in success NTRB could attain annual revenue in the $10Mn to $15Mn range by 2025-26 on its way to achieving scale and peak sales, depending on the commercialization timeline. We believe these forecasts are supported by the growing size of the target markets and AVERSA’s expected ability to improve the safety profile of fent-a-nyl and other prescription medications. Moreover, we also believe that competitive pressure could lead to adoption of the AVERSA technology by several large pharma companies in a short period, if the technology proves as efficient as NTRB believes it will. In fact, fent-a-nyl transdermal patches have become such an important pain therapy that they have been added to the WHO list of essential medicines, as noted, which we believe supports the positive outlook for AVERSA if clinical test results support its efficacy and safety. If the company can maintain its expected timeline and commercialize AVERSA by late 2024, our forecast could prove conservative, depending on several factors.
It is difficult to compare NTRB to other more mature companies, in our view, given the early stage of development of AVERSA and the product portfolio. We would also expect NTRB to have a higher growth rate in the early years. Various other companies that are engaged in introducing new therapies and solutions and are at a similar stage of development have a wide range of price-to revenue multiples on forward estimates. Nevertheless, we believe the average price-to-sales multiple of companies in this comparison of about 14x provides a valuation benchmark for NTRB. Therefore, applying a 14x multiple to our above-noted forecast revenue range and discounting back to the present at 10%/year results in a present value of about $10 to $15 per share on a fully diluted basis, if the company initiates a successful launch of AVERSA. We expect the shares to begin to reflect the low end of this range as it hits certain milestones and incorporate the mid- to high-end as AVERSA development proceeds. Our forecast could change if and when the company expands the number of products leveraging the AVERSA technology.
While there are several risks to the timeline and commercial launch, we think the current share price does not reflect the fundamental value of the company’s pipeline and prospects and would anticipate multiple expansion as the company continues to advance AVERSA. Any delay or failure in clinical development or regulatory approval could cause the share price to decline and represent a potential risk to our valuation but we believe the risk / reward ratio could be attractive for in-vest-ors who have a higher than average risk tolerance and longer time horizon.
No. 3 NTRB Potential Catalyst - Major Revenue Jump Shows The Potential For An Increasingly Bright Future
Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3
ORLANDO, FL / ACCESSWIRE / December 5, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022.
- Generated record quarterly revenue of $620k, up 118% over Q3 2021
- Revenue for nine-months ended October 31, 2022, was $1.55+Mn, up 67% year-over-year
- Continued to expand AVERSA™ intellectual property portfolio with patents now issued in 44 countries; AVERSA™ patent coverage includes the U.S., Canada, Europe, Japan, Korea, Mexico, Australia, and Russia, with patents pending in China
- Demonstrated with Kindeva Drug Delivery enhanced abuse-deterrent characteristics for Aversa Fent-a-nyl
- Applied for Dual Listing on Upstream
- St-ockholders' equity of $9.7Mn as of October 31, 2022
"Once again, we have had a record quarter for our revenue generating subsidiaries. Building on these revenue streams remains an important focus for us as we continue to develop AVERSA Fent-a-nyl," commented Gareth Sheridan, CEO of Nutriband. "According to the assessment by Health Advances, AVERSA Fent-a-nyl could reach peak annual sales of between $80 to $200Mn. If the entire transdermal fent-a-nyl market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater. We are continually thankful to our shareholders for their ongoing support as we continue to execute on our vision of commercializing AVERSA.''
Q3 2022 Financial Highlights:
Revenue for the three-months ended October 31, 2022 was $0.6Mn, up 118% from revenue of $0.28Mn in the third quarter of fiscal year 2021. Revenue growth was driven primarily by increasing demand for the Company's Pocono Pharmaceuticals segment.
Read the full article here.
No. 4 NTRB Potential Catalyst - A Recent Listing Could Provide Unquantifiable Exposure For NTRB
Nutriband Inc. Commences Trading on Upstream Under NTRB
Nutriband among the first issuers to dual list on Upstream
ORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".
"We are thrilled to be amongst the first companies to dual list on Upstream's next generation marketplace," says Gareth Sheridan, CEO of Nutriband. "We are adding new value to our shareholders while expanding our company and mission to a modern, global in-vest-or-base."
Read the full article here.
No. 5 NTRB Potential Catalyst - New Patent Protects AVERSA Transdermal Abuse Deterrent Technology
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent
ORLANDO, FL / ACCESSWIRE / December 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. This patent protects Nutriband's AVERSA™ transdermal abuse deterrent technology being developed to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential that are delivered with a transdermal patch.
The issuance of this Canadian patent in combination with patents already issued in the United States and Mexico provides intellectual property protection for Nutriband's Aversa™ products across North America. In addition, the Aversa™ abuse deterrent technology is covered by a broad intellectual property portfolio with patents already granted in the United States, Europe, Japan, Korea, Russia, and Australia.
Read the full article here.
NTRB Recap - 5 Key Potential Breakout Catalysts For This Nasdaq Idea
No. 1 - Low Float Volatility Could Take Hold At A Moment's Notice
No. 2 - Analyst From Zacks SCR Provides Massive $10 Target
No. 3 - Major Revenue Jump Shows The Potential For An Increasingly Bright Future
No. 4 - A Recent Listing Could Provide Unquantifiable Exposure For NTRB
No. 5 - New Patent Protects AVERSA Transdermal Abuse Deterrent Technology
Coverage is officially initiated on NTRB. To ensure receiving all updates, do this: